Sanofi

Sanofi, a French Pharmaceutical Preparation Manufacturing company, reported its latest emissions in 2025 with an estimated total of approximately 4.45 billion kg CO2e. This includes about 235 million kg CO2e from Scope 1 emissions, 70 million kg CO2e from Scope 2 (market-based), and approximately 3.44 billion kg CO2e from Scope 3 emissions.

In 2024, Sanofi's total emissions were approximately 4.66 billion kg CO2e, comprising about 261 million kg CO2e for Scope 1, 81 million kg CO2e for Scope 2 (market-based), and roughly 3.40 billion kg CO2e for Scope 3. Looking back to 2023, the company's total emissions stood at approximately 4.80 billion kg CO2e, with Scope 1 at about 288 million kg CO2e, Scope 2 (market-based) at 83 million kg CO2e, and Scope 3 at roughly 3.79 billion kg CO2e.

Sanofi has committed to several ambitious climate targets. The company aims to achieve net-zero greenhouse gas emissions across its entire value chain by 2045, from a 2019 baseline year. This long-term target is supported by a near-term commitment to reduce absolute Scope 1 and 2 GHG emissions by 55% by FY2030, also from a FY2019 base year. Additionally, Sanofi plans to increase its annual sourcing of renewable electricity from 11% in FY2019 to 80% by FY2025 and 100% by FY2030. For Scope 3 emissions, Sanofi commits to a 30% absolute reduction by FY2030 from a FY2019 base year, specifically targeting purchased goods and services, capital goods, fuel and energy related activities, upstream transportation and distribution, waste generated in operations, business travel, and employee commuting. These targets, including the net-zero commitment by 2045 and the 90% absolute reduction across Scope 1, 2, and 3 by 2045 from a 2019 base year, have been validated by the Science Based Targets initiative (SBTi) as consistent with limiting global warming to 1.5°C. Sanofi has also communicated an ambition to reach carbon neutrality by 2030 across its entire value chain.